New drug could free patients from daily calcium pills

NCT ID NCT05778071

Ongoing Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 35 times

Summary

This phase 3 trial tests eneboparatide, a lab-made hormone, in 165 adults with chronic hypoparathyroidism. The goal is to see if it can help patients stop taking high-dose calcium and vitamin D supplements while keeping calcium levels normal. Participants receive either the drug or a placebo for 24 weeks, then all receive the drug for up to 132 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Aarhaus University Hospital

Aarhus, 8200, Denmark
Academy of Diabetes, Thyroid and Endocrine

El Paso, Texas, 79935, United States
Arthritis Northwest, PLLC

Spokane, Washington, 99204, United States
Azienda Ospedaliera Universitaria Careggi

Florence, 50134, Italy
Azienda Ospedaliera Universitaria Pisana-Ospedale di Cisanello

Pisa, 56124, Italy
Azienda Ospedaliero Universitaria de Bologna, Policlinico Sant Orsola Malpighi

Bologna, 40138, Italy
Bone Research and Education Center

Oakville, Ontario, L6M 1M1, Canada
CHU de Nantes - Hôtel-Dieu

Nantes, 44093, France
CHU de Quebec Research Centre

Québec, G1V 4G2, Canada
Cendrum Zdrowi MDM - EB Group Sp.

Warsaw, 00189, Poland
Centro Hospital Vila Nova de Faia/Espinho

Porto, 4434-502, Portugal
Churchill Hospital

Oxford, OX3 7LE, United Kingdom
Clinica Universidad de Navarra

Pamplona, 31008, Spain
Colombia University Irving Medical Center

New York, New York, 10032, United States
Complejo Hospitalario Universitario de A Coruna

A Coruña, 15006, Spain
Denver Endocrinology Diabetes and Thyroid Center

Denver, Colorado, 80113, United States
Eastern Regional Health Authority Health Sciences Centre

St. John's, Newfoundland and Labrador, A1B 3V6, Canada
Eramus MC - University Medical Center

Rotterdam, 3015 GD, Netherlands
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

Milan, 20122, Italy
Harbor UCLA Medical Center Endocrinology

Torrance, California, 90502, United States
Hopital de la Conception-APHM

Marseille, 13385, France
Hospital Bicetre AP-HP

Paris, 94275, France
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitario Virgen del Rocio

Seville, 41013, Spain
Hospital da Luz Lisboa

Lisbon, 1500-650, Portugal
Indiana University (IU) Health University Hospital

Indianapolis, Indiana, 46202, United States
Instytut Centrum Zdrowia Matki Polki. Klinika Endokrynologii Chorob Metabolicznych

Lodz, 93-338, Poland
Kanazawa University Hospital

Kanazawa, Japan
Leiden University Medical Center

Leiden, 2333, Netherlands
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Medicover Neuroendokrinologie MVZ

Munich, 81667, Germany
Medycyny Nuklearnej i Chorob Wewnetrznych

Krakow, 30-688, Poland
Norfolk & Norwich University NHS Foundation Trust, Quadrum Institute

Norwich, NR4 7UQ, United Kingdom
North Shore University Health System

Evanston, Illinois, 60201, United States
Northern Nevada Endocrinology

Reno, Nevada, 89511, United States
Osaka City Hospital

Osaka, Japan
Osaka Metropolital University Hospital

Osaka, Japan
Pecsi Tudomanyegyetem

Pécs, 7624, Hungary
Physician's East Endocrinology

Greenville, North Carolina, 27834, United States
Rigshospitalet

Copenhagen, Denmark
Semmelweis Egyetem Belgyogyaszati es Hematologiai Klinika

Budapest, 1083, Hungary
Teikyo University Chiba Medical Center

Chiba, Japan
The Children's Hospital of Philadelphia (CHOP)

Philadelphia, Pennsylvania, 19104, United States
The Children's Hospital of Philadephia

Philadelphia, Pennsylvania, 19104, United States
The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
Tokushima University Hospital

Tokushima, Japan
Tottori University Hospital

Tottori, Japan
Universitaetsklinikum Wuerzburg

Würzburg, 97080, Germany
Universitatsklinikum Carl Gustav Carus an der TU Dresden

Dresden, 01307, Germany
University Hospitals of Leicester NHS Trust

Leicester, LE1 5WW, United Kingdom
University of Chicago - Medical Center

Chicago, Illinois, 60637, United States
Via Alvaro del Portillo, 200, Roma, Italy 00128

Roma, 00128, Italy

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

eneboparatide (AZP-3601), a synthetic hormone that mimics natural parathyroid hormone

What this could lead to

If successful, this treatment could help people with chronic hypoparathyroidism reduce or stop daily calcium and vitamin D supplements, improving their quality of life.

What could go wrong

This is a phase 3 trial, but results are not yet known. The drug may not work better than placebo, and side effects could occur. Long-term safety is still being studied.

Conditions

The condition(s) this trial relates to.

endocrine system disorder hypoparathyroidism parathyroid gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HYPOPARATHYROIDISM ENDOCRINE SYSTEM DISEASES ENDOCRINE SYSTEM DISEASES PARATHYROID DISEASES